NitricBio Selects Clinipace Worldwide to Manage Multiple Clinical Trials
News Jan 14, 2010
Clinipace Worldwide has announced that NitricBio has selected the company to manage and deploy multiple studies in support of medical applications of topical nitric oxide gas (gNO).
“Their approach towards a fully-integrated technology-driven clinical research model will help us drive greater trial visibility, more project control, and, ultimately, lower costs for each of our four trials.”
NitricBio is a mid-stage specialty pharmaceutical company focused on the dermatology and podiatry markets, with two unique drug delivery technologies. The company awarded Clinipace Worldwide a four-project engagement, including data management, statistical services, and medical writing for two phase 2 trials as well as providing fully-integrated clinical research services to manage and conduct two phase 3 trials.
“Clinipace Worldwide offered the global experience and full-service expertise we were looking for in a CRO partner,” said Tanya Rhodes, chief technology officer, NitricBio. “Their approach towards a fully-integrated technology-driven clinical research model will help us drive greater trial visibility, more project control, and, ultimately, lower costs for each of our four trials.”
In addition to delivering clinical development services, Clinipace Worldwide will deploy its web-based technology platform to collect, manage, and monitor study data, which will greatly streamline associated processes and trial timelines for NitricBio.
“Clinipace Worldwide is committed to providing innovative companies like NitricBio with a full-range of development solutions and expert services to match any size clinical study and operational approach,” said Christopher Porter, chief operating officer, Clinipace.
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE